Dr. Reddy’s Laboratories expands wellness portfolio with MenoLabs acquisition

TAGS

In a significant move within the healthcare industry, Dr. Reddy’s Laboratories Ltd. has announced the acquisition of the MenoLabs business, a prominent player in women’s health and dietary supplements, from Amyris, Inc. This acquisition occurred during Amyris’ Chapter 11 sales process.

At the forefront of this deal is the entire portfolio of MenoLabs supplements, which includes seven branded products. These products are specially designed to support health and address symptoms associated with perimenopause and menopause. The brands under this deal include MenoFit and MenoGlow probiotics, Happy Fiber and Well Rested dietary supplements, Athena’s Shield menopause support supplement, and Goodness Glow and Keep Glowing Gorgeous supplements for healthy aging support. Additionally, the deal encompasses the MenoLife health tracker app, which complements the product line by providing community support, education, and information regarding menopause.

Dr. Reddy's Acquires Leading Women’s Health Brand MenoLabs from Amyris, Inc.

Dr. Reddy’s Acquires Leading Women’s Health Brand MenoLabs from Amyris, Inc.

Expanding Market Reach and Addressing Women’s Health Needs

Primarily sold in the United States, the MenoLabs portfolio is available through its website and other e-commerce platforms like Amazon and Walmart. This acquisition is a strategic move by Dr. Reddy’s to strengthen its position in the fast-growing women’s nutritional and wellness markets. Marc Kikuchi, Chief Executive Officer for Dr. Reddy’s in North America, emphasized that the acquisition will serve as a catalyst to accelerate growth in this domain. He also highlighted the alignment of this acquisition with Dr. Reddy’s aspiration to lead in women’s wellness markets.

See also  Dr. Reddy's Laboratories debuts generic version of KOMBIGLYZE XR in US

Kikuchi further added, “The acquisition complements Dr. Reddy’s U.S. self-care and wellness business portfolio of brands and addresses unmet needs of consumers for science-based, research-driven products that provide relief from the symptoms of menopause. For these and many other reasons, I believe we are well-positioned to successfully integrate and grow the business.”

See also  Dr. Reddy’s launches Sapropterin Dihydrochloride Tablets generic version in US

The addition of MenoLabs to Dr. Reddy’s portfolio is expected to broaden the company’s offerings in the women’s health sector, providing a more comprehensive range of products to meet the diverse needs of this demographic. This move underscores Dr. Reddy’s commitment to delivering innovative health solutions and expanding its footprint in the global wellness market.

CATEGORIES
TAGS
Share This